The company's scientific advisors met in Bilbao to evaluate the clinical progress of their lead candidate, the Quantum ADC platform, and the design of bispecific ADCs, as well as to help define the next steps in their R&D strategy.
DERIO, October 6, 2026 – Oncomatryx met its Scientific Advisory Board (SAB) in Bilbao on September 30. The SAB brings together external scientists who advise the company on research matters, and the meeting had a clear objective: to share the advances and achievements of Oncomatryx’s R&D programs, discuss them with the advisors, and gather their opinions in order to align with the company’s strategy and the next steps to be taken.
The CEO, Laureano Simón, opened the session and welcomed the attendees before handing over the floor to the Chief Scientist Officer, Myriam Fabre, who presented the overview of the current situation and the prospects for the company’s OMTX ADC products. From there, the day was organized into three blocks:
The first focused on OMTX705, the company's lead candidate, an antibody-drug conjugate (ADC) targeting the tumor microenvironment that is already in Phase Ib-II clinical trials in reference hospitals in Spain and the United States. The Chief Medical Officer, Ignacio García, presented the status of the trial and the development plan, and Patricia González, Translational Science R&D Director, explained the candidate's mechanism of action and the biomarkers used to select patients.
The second block went beyond OMTX705 to focus on Quantum ADCs, the next generation of ADCs directed against the company’s FAP. Isabel Egaña, NextGen ADCs R&D Director, presented the next candidate in the development pipeline, as well as the intelligent ADCs that will follow. Next, the chemistry team from Quimatryx, the company’s chemical subsidiary, represented by Yosu Vara and Julie Movellan, presented the new «superlinkers» that attach the antibody to its payload, and Andoni Berbel, director of AI, explained how the company uses artificial intelligence and quantum computing to design and select these candidates.
The third block, led by Professor Roland Kontermann from the University of Stuttgart, addressed biexponential ADC and antibody chemistry as well as the chemistry related to cytotoxic loading with Wolfgang Richter. The final session before the final deliberations, led by Ana Soloaga, Fibrosis & Women’s Health R&D Director, explored the potential applications of the company’s directed-against-FAP ADC beyond oncology.
For Oncomatryx, the meeting provided an opportunity to present its programs to its scientific advisors and to seek their expert opinions. Those opinions are what allow the company to align its strategic priorities, set the next steps for each program, and define its future development paths as it advances in its mission to offer new therapeutic options to patients who need them.
About Oncomatryx
Oncomatryx is a Spanish biopharmaceutical company, based in the Basque Country and with a global perspective, pioneering the treatment of metastatic solid tumors through its microenvironment, rather than directly acting on the tumor epithelial cell. The company has also created a platform designed to generate multiple candidates and bring them to clinical proof of concept in order to grant licenses to major pharmaceutical companies, covering the entire cycle of research, clinical development and in-house manufacturing that today defines industry leaders.
Oncomatryx is the only biotechnology company designated as strategic by the Center for Industrial Technological Development (CDTI) of Spain and has received a grant in 2025 from the European Union’s EIC Accelerator program, being one of the five companies in the life sciences sector selected from 950 applicants.